… Thangarajh M, Gomez-Rial J, Hedstrom AK, et al. Lipid-specific immunoglobulin M in
CSF predicts adverse long-term outcome in multiple sclerosis. Mult Scler J 2008; 14: 1208–1213. …

… Our risk estimates calculated from patient-level clinical data allow individualised annual
prediction of risk of PML in patients receiving natalizumab for multiple sclerosis, supporting …

… with multiple sclerosis (MS), but the mechanisms leading to axonal damage are poorly
understood. Oligoclonal IgM against lipids predicts … The presence of lipid-specific oligoclonal IgM …

… Current PML risk stratification includes the factors long-term treatment with natalizumab, 1
… a similar hypothesis: a lack of intrathecal, lipid-specific IgM bands and lack of L-selectin on …

… the presence of depleted CSF B and T cells … long-term CD20-targeted B cell depletion
therapy may impact plasma cells in treated patients and thereby alter antibody levels, but antibody …

… Factors predicting poorer prognosis in CIS include high MRI lesion … Presence of
immunoglobulin M (IgM) OCBs,56, 57 and … We consider lipid-specific IgM OCBs to be a useful, …

… for these anti-GalCer antibodies in order to predict conversion to clinically definite MS.
Antibodies in … Pursuing the GL and lipid-specific cells in MS will yield insights into lipid use in anti-…

… RRMS patients with lipid-specific immunoglobulin M (IgM) … Predictors of long-term outcome
in multiple sclerosis patients … alemtuzumab does not predict multiple sclerosis activity. …

… Our short review argues for a probable faint ITS in the rare ‘CSF‐negative’ patients, making
ITS … diversity and pathogenicity might help to decipher the crucial problem of predicting the …

… of antibodies in multiple sclerosis (MS) physiopathology. Thus, local IgG synthesis is a
hallmark of the disease, and intrathecal IgM synthesis associates with a poor disease outcome. …